WebPipeline. IDEAYA is pursuing precision medicine therapeutics, with a broad pipeline based on synthetic lethality – an emerging area of precision medicine oncology. IDE196 (darovasertib), a PKC inhibitor, is a clinical stage development compound for patients with tumors harboring GNAQ or GNA11 mutations, including in metastatic uveal melanoma ... WebNov 22, 2024 · Christian Frey is an Associate Director at IDEAYA Biosciences based in South San Francisco, California. Previously, Christian was a Scientist at G ilead and …
Christian Frey Profiles Facebook
WebPipeline. IDEAYA is pursuing precision medicine therapeutics, with a broad pipeline based on synthetic lethality – an emerging area of precision medicine oncology. IDE196 … WebJun 28, 2024 · IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination ‒ Observed plasma SAM reduction in each of the first two dose ... disney magic band pin
Christian Frey on LinkedIn: IDEAYA Receives Authorization …
WebJul 27, 2024 · IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to clinical evaluation of IDE397 in combination with … WebApr 16, 2024 · SOUTH SAN FRANCISCO, Calif., April 16, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical data from the ongoing Phase 1/2 trial evaluating darovasertib … WebChristian Frey’s Post. Christian Frey 3y Report this post Julie Hambleton 3y Pleased to be moving forward to study IDE196, a potent, selective PKC inhibitor, in patients with … cowshed charity winnersh